BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
51
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 36m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BLINCYTO (blinatumomab) is a bispecific antibody that engages T cells to target B-lineage acute lymphoblastic leukemia (ALL). It bridges CD19-expressing leukemia cells with CD3+ T cells to enable cytotoxic T-cell killing. This mechanism enables treatment of relapsed/refractory ALL and minimal residual disease (MRD).
$0.002BPart D
PeakProduct remains in peak lifecycle stage with modest Part D utilization; stable commercial foundation supports focused teams rather than expansion hiring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (51)
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
Started Jun 2028
560 enrolled
Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
Started Jan 2027
60 enrolled
Phase II Clinical TrialBlinatumomabOlverembatinib+2 more
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL
Started Jan 2027
80 enrolled
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)BCR-ABL Positive Acute Lymphoblastic Leukemia
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
Started Dec 2026
26 enrolled
Philadelphia Positive Acute Lymphoblastic Leukemia
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
Started Nov 2026
20 enrolled
BlinatumomabRevumenibLymphoblastic Leukemia+1 more
Worked on BLINCYTO at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.